Carpometacarpal osteoarthritis (CMC-OA
well known that the pharmacological treatment, particularly in the elderly, may cause relevant side effects on gastrointestinal, renal, hepatic and cardiovascular systems (5) , therefore, drugs with minimal side effects are warranted.
The use of intra-articular steroids is controversial: some authors (6) have observed positive results, but a recent double-blind randomised controlled trial against placebo failed to detect a clinical benefit in moderate to severe CMC-OA (7) . When the conservative approach fails and function is severely impaired, surgical treatment becomes necessary (8) .
Hyaluronic acid (HA) is essential for articular homeostasis; it has a protective effect on articular cartilage and the soft tissue surfaces ofjoints, acting as a lubricant and imparting viscoelastic properties to the joint because of its high viscosity (9) . In OA the concentration of HA and viscoelasticity of synovial fluid in the joints are reduced; therefore, the transmission of mechanical force to cartilage may increase its susceptibility to mechanical damage. This is the biological basis for the administration of HA into the OA joints in order to restore the normal articular homoeostasis (9) .
Viscous supplementation by intra-articular injections of HA has beneficial effects in the knee and hip OA in selected patients and has been recommended by expert panels as an effective symptomatic slow acting treatment (9) (10) (11) (12) . The treatment with HA has also been shown useful in CMC-OA, with pain reduction and functional improvement (3, (13) (14) (15) . However, few trials have been published and the total number of cases treated is at present scanty. The aim of the present paper is to report the results obtained on pain and hand function after one single ultrasound guided injection of HA, inCMC-OA.
MATERIALS AND METHODS
Patients attending the Orthopaedic Department of the University Hospital ofChieti with symptomatic CMC-OA were enrolled. All patients satisfied the American College of Rheumatology (ACR) criteria (16) for the classification of hand OA, and had CMC-OA grade 2-3 according to Kellgren and Lawrence criteria (17) , on standard X-ray performed within 3 months of inclusion. Only patients suffering more than one month were included. We excluded patients with a history of inflammatory arthritis, previous thumb base trauma, previous intraarticular injection with steroids or HA to either CMC or in treatment with anticoagulants. Moreover, patients with a known allergy or other contraindications to administered reagents, or critical skin conditions at the injection site were excluded. Written consent was obtained from each participant.
Assessment
Full patient assessment was carried out at baseline. Demographic data (sex, age, weight, height) were collected for all subjects. Pain of CMC joint, at rest and during common activities of daily living, was assessed using 10 em visual analogue scale (VAS), with 0 representing no pain and 10 representing the worst pain (18) . Weekly NSAID consumption was recorded.
Functional assessment was carried out using the Dreiser Functional Index for hand OA (19) . Grip strength was measured using a standard adjustable-handle Jamar dynamometer in the sitting position, with the shoulder adducted and neutrally rotated, and the elbow flexed at 90 0 • Lateral and pulp pinch strength were measured by a hydraulic pinch gauge in the same position (20) .
Treatment
We used a sterile I ml pre-filled syringe containing HA, with a molecular weight of 0.8 to 1.2 million Dalton, at a concentration of 0.8%, to be directly injected into the articular space. Patients were positioned with the hand to be injected held in the semi-prone position. Preliminary ultrasound investigation of the CMC joint was carried out in order to evaluate joint space and to record osteoarthritic changes (Fig. I) . The CMC space was identified by palpation and the needle tip was inserted lateral to the abductor pollicis longus tendon. The proper position of the needle into the CMC joint was confirmed by real-time ultrasound, therefore HA was injected (Fig. 2) . After the injection, the patients returned to their homes with the advice not to use the hand throughout the day. Local side effects after the injection, such as swelling, redness and heat, were recorded. The use of analgesic, in case of intolerable pain, was allowed.
Follow-up
Clinical assessment, as described above, was repeated after one month by the same investigator who carried out the baseline pre-injection assessment.
Statistical Analysis
Data are reported as Mean±Standard Errors, for continuous, and as frequencies and percentage for dichotomous and categorical variables. Differences between baseline and follow-up were evaluated by In t. J. Immunopathol. Pharmacol. 
RESULTS
In the present study 18 subjects (11 female, 7 male) were injected. The mean age of the patients was 70.6 years ± 7.2. In 2 cases, CMC-OA was bilateral; 13 right (65%) and 7 left (35%) CMC joint were treated. According to Kellgren and Lawrence criteria, the number of hands with X-ray CMC-OA grade 3/2 was 14 (70%) and 6 (30%), respectively. Average symptoms duration was 7.3 months ± 2.4. Mean volume ofHA injected was 0.86 ± 0.13.
As shown in Table I , VAS pain score, which, at rest, was 1.8 ± 1.07, decreased to 0.5 ± 0.68, after treatment (-72.22%). Pain score during activities also decreased from 8.05 ± 0.94 to 4.15 ± 1.42. (-48.44 %). Dreiser Functional Index increased from 18.5 ± 3.31 to 20.7 ± 2.77 (+11.59%). The hand grip strength, the lateral pinch strength and the pulp pinch strength showed an increase of 1.64%, 6.74% and 24.07%, respectively.
The use ofNSAIDs was registered in 16 subjects (80%) with a weekly assumption of 2.45 ± 1.98 tablets at baseline; after treatment only 7 subjects (35%) were on treatment with NSAIDs and the number of pills per week was also reduced (1.15 ± 1.30). Mild side effects (pain and/or swelling and/or heat and/or redness) were observed only in 2 patients. These effects lasted less than 3 h, without the use of any medications.
DISCUSSION
Our results show that a single injection of HA is effective in treating CMC-OA. After therapy the VAS pain score, both at rest and during common daily activities, substantially decreased, whereas the hand function and strength were clearly improved. As expected, the best improvement was observed in the pulp pinch strength, because the CMC joint is strongly stressed in this movement, therefore a better mobility and a reduction of pain in the joint allow an evident increase in performance. The use ofNSAIDs was also clearly reduced. These findings are in agreement with the results reported in previous trials (3, (13) (14) . Fuchs and Stahls (1), after 3 injections of HA (one/week), observed a significant improvement of symptoms and function after one month, which persisted after 3 and 6 months. Moreover, Roux et al. (3) reported a significant effect in terms of pain and functionality as early as the first month with persistent effects at 3 months.
The effects of HA on grip strength, evaluated with dynamometry, are reported in two studies, with significant improvement only at 6 months (1). In our experience, positive results were obtained after a single HA injection and a shorter follow-up period.
The mechanisms of the therapeutic action of HA are not fully understood. Because the positive effects persist for many months after the injection, they cannot be solely attributed to viscous supplementation and restoration of joint rheology itself, but also may be mediated by several pathways such as anti-inflammatory and antinociceptive effects, normalization of endogenous HA synthesis, and chondroprotection (21) . These activities are suggested by studies in experimental OA in rabbits, which show that HA inhibits matrix metalloproteinase (MMP)-3 production and decreases the synovial expression of interleukin 1 beta (22) . Therefore, the chain of events that, from fibronectin fragments via cytokines, leads to a reduced synthesis of proteoglycans, is blocked (22) .
It is important to underline that the injection of HA must be performed under ultrasound guidance. This procedure is simple, fast (5 minutes), economic and safe. It allows an easy visualization of the joint, shows how narrow the articular space is and makes sure that HA is injected properly inside the joint. Indeed, if HA is injected into the extra-articular space, its therapeutic activity is completely lost.
Some limitations of our study must be acknowledged. Firstly, because of the open design of the trial, a placebo effect cannot be ruled out. However, the extent of improvement in reduction of pain largely exceeds that observed after intraarticular injection of placebo in OA joints, which usually ranges from 15% to 30% (23) (24) . Secondly, the short duration of follow-up does not allow to evaluate how long the therapeutic effect is maintained.
In conclusion, the ultrasound-guided injection of HA is very effective in the treatment of CMC-OA, restoring the hand function and reducing the functional impairment in daily living activities.
The absence of systemic or local side effects and the high tolerability of HA allows the contemporary use ofother drugs, which may be helpful, in polydrugtreated patients. However, in order to confirm these promising data and to recognize the patients who are better responders, large scale double-blind controlled studies with a longer follow-up period are needed.
